Zydus Lifesciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+16.8%+18.9%+13.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+20.1%+31.1%+39.5%
+15.0%+33.0%+47.3%
+9.6%+17.6%+89.9%
+11.4%+17.9%+97.6%
+40.9%+27.1%+13.7%
+12.2%+19.3%+12.3%
−68.8%+109.9%+20.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZYDUSLIFE₹1,175.50

Zydus Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLATORNTPHARMDIVISLABMAXHEALTHAPOLLOHOSPAUROPHARMAMcap ₹1.18L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+13.4+18.9+16.8—
EBITDA Growth—+39.5+31.1+20.1—
EBIT Growth—+47.3+33.0+15.0—
Net Income Growth—+89.9+17.6+9.6—
EPS Growth—+97.6+17.9+11.4—
Total Assets Growth—+13.7+27.1+40.9—
Total Equity Growth—+12.3+19.3+12.2—
Cash from Operations Growth—+20.0+109.9-68.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.